Search EFSA Journal
Suche verfeinern
Art
All article types
Special Issue Item
Journal Editorial
Scientific opinions of Scientific/Scientific Panel
Opinion of the Scientific Committee/Scientific Panel
Statement of the Scientific Committee/Scientific Panel
Guidance of the Scientific Committee/Scientific Panel
Other scientific outputs of EFSA
Statement of EFSA
Guidance of EFSA
Conclusion on pesticides
Reasoned opinion on pesticide
Scientific report of EFSA
Technical Report
Subject
All subjects
Animal health & welfare
Biological hazards
Biological monitoring
Contaminants
Dietary & chemical monitoring
Emerging risks
Feed
Food Ingredients and Packaging
GMO
Nutrition
Pesticides
Plant health
Assessment and methodological support
Scientific Committee
Scientific cooperation
Article ID
Digital Object ID
Sort by:
Publication date
Relevance

Scientific Opinion on the substantiation of a health claim related to eicosapentanoic acid (EPA) and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms” pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Journal 2013;11(4):3161[10 pp.]. doi:10.2903/j.efsa.2013.3161
  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Panel Members Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen Acknowledgment The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the preparatory work on this scientific opinion. Contact nda@efsa.europa.eu
Type: Opinion of the Scientific Committee/Scientific Panel On request from: Competent Authority of Belgium following an application by Minami Nutrition Health BVBA Question number: EFSA-Q-2012-00573 Adopted: 21 March 2013 Published: 08 April 2013 Affiliation: European Food Safety Authority (EFSA), Parma, Italy
Abstract

Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to eicosapentaenoic acid (EPA) and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with attention deficit hyperactivity disorder (ADHD)-like symptoms”. The food constituent, EPA, which is the subject of the health claim, is sufficiently characterised. The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour”. Upon a request by EFSA for clarification, the applicant indicated that the disease was ADHD, which is classified as such in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), that the risk factor for the disease was an elevated AA/EPA ratio in blood, and that the target population for the claim was children with diagnosis of ADHD. The Panel considers that the evidence provided does not establish that reducing the AA/EPA ratio reduces the risk of ADHD in children, and considers that the target population is a diseased population (i.e. children with ADHD). The Panel concludes that the claimed effect relates to the treatment of a disease, and that therefore the health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

© European Food Safety Authority,2013

Summary

Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to eicosapentaenoic acid (EPA) and “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms”. The scope of the application was proposed to fall under a health claim referring to disease risk reduction.

The Panel considers that the food constituent, EPA, which is the subject of the health claim, is sufficiently characterised.

The claimed effect proposed by the applicant is “reduces the AA/EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with attention deficit hyperactivity disorder (ADHD)-like symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour”. The target population proposed by the applicant is “children 5-13 years of age with ADHD-like symptoms and low blood levels of omega-3 fatty acids”.

Upon a request by EFSA for clarification in relation to the proposed claimed effect, the validity of the risk factor proposed for the disease, and the target population, the applicant indicated that the disease was ADHD, which is classified as such in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), that the risk factor for the disease was an elevated AA/EPA ratio in blood, and that the target population for the claim was children with diagnosis of ADHD.

No evidence was provided by the applicant to substantiate that the AA/EPA ratio plays a role in the development of ADHD, that the AA/EPA ratio can predict the incidence of ADHD, or that lowering the AA/EPA ratio can lower the risk of ADHD.

The Panel considers that the evidence provided does not establish that reducing the AA/EPA ratio reduces the risk of ADHD in children.

The Panel notes that the target population for the claim is a diseased population (i.e. children with ADHD).

The Panel concludes that the claimed effect relates to the treatment of a disease, and that therefore the health claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

Keywords

Eicosapentaenoic acid, EPA, arachidonic acid, AA/EPA ratio, attention deficit hyperactivity disorder, ADHD, health claims